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Abstract: This review identifies evidence on supply-side interventions to change the practices of
antibiotic prescribers and gatekeepers in low- and middle-income countries (LMICs). A total of 102
studies met the inclusion criteria, of which 70 studies evaluated interventions and 32 provided insight
into prescribing contexts. All intervention studies were from human healthcare settings, none were
from animal health. Only one context study examined antibiotic use in animal health. The evidence
base is uneven, with the strongest evidence on knowledge and stewardship interventions. The review
found that multiplex interventions that combine different strategies to influence behaviour tend to
have a higher success rate than interventions based on single strategies. Evidence on prescribing
contexts highlights interacting influences including health system quality, education, perceptions of
patient demand, bureaucratic processes, profit, competition, and cultures of care. Most interventions
took place within one health setting. Very few studies targeted interventions across different kinds of
providers and settings. Interventions in hospitals were the most commonly evaluated. There is much
less evidence on private and informal private providers who play a major role in drug distribution
in LMICs. There were no interventions involving drug detailers or the pharmaceutical companies
despite their prominent role in the contextual studies.
Keywords: antibiotic resistance; antibiotic prescribing; antibiotic use; antibiotic stewardship
1. Introduction
Globally, antibiotic use is increasing, up 65% between 2000 and 2015 [1]. The majority of this
increase has been caused by rapid expansion of use in low- and middle-income countries (LMICs).
Consumption rates in many LMICs are catching up with higher-income countries [1] but usage is
often unnecessary due to lack of supportive regulation and widespread informal use [2]. While access
to antibiotics is of clear public health benefit, the inappropriate use of antibiotics is a major driver
of antibiotic resistance [3] and requires urgent attention. To inform context-appropriate policy in
LMICs, we conducted a review of supply side interventions and their impact on unnecessary and
inappropriate use of antibiotics in human and animal health systems. The aim was to determine the
evidence base for changing the practices of antibiotic prescribers and gatekeepers in LMICs.
Previous systematic reviews have found evidence to support a range of effective and safe
interventions to reduce antibiotic prescribing in human health settings. Interventions that combine
restrictive and enabling policies have shown better results [4]. Interventions that are interactive
and multi-faceted have stronger effects, for example education with feedback and monitoring
mechanisms [5,6]. However, the majority of studies included in these reviews are from high-income
countries, and within that a limited range of settings (e.g., in-patient prescribing) and methods.
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One review [6] looked specifically for evidence on doctor’s prescribing in primary care in upper
middle-income countries. However, their review only included eight studies and the authors noted
that the quality of evidence was limited. We are not aware of any reviews of prescribing interventions
in animal health settings. Taken together, these reviews have found encouraging results but there are
questions about how generalizable they are beyond the specific targeted groups (e.g., doctors) and
homogenous prescribing contexts (e.g., formal providers in relatively well organised human health
systems in high-income countries). LMICs, as defined by World Bank, include a variety of health
system arrangements, which makes generalizations difficult. However, in many, the human and
animal healthcare contexts can be described as “pluralistic”, where people consult a variety of public,
private, traditional, biomedical, formal and informal providers, and where the capacity of governments
to regulate these providers is variable, and is increasingly recognised as a major concern [7]. Effective
action is complicated by high rates of infection due to poor preventative public health combined with
inconsistent and inequitable access to essential medicines. As such, research on LMICs interventions
and contexts is urgently needed and is the focus of this review.
The monitoring of unintended consequences requires particular attention as the supply and
distribution of antibiotics has the potential to include competing objectives and is sensitive to
interventions not specifically targeting antibiotic use. For example, the use of rapid diagnostic tests to
improve malaria diagnosis has led to an increase in antibiotic use in some settings [8,9].
The review set out to answer the following questions (for human and animal health systems):
- What supply-side interventions have been tried in LMICs to reduce inappropriate antibiotic
prescribing and sale?
- Where have interventions been implemented e.g., country and kind of health care settings?
- Which kinds of interventions have shown promise in reducing inappropriate prescribing?
- What information exists on the contexts of interventions and attempts to influence antibiotic use
and prescribing?
2. Methods
We carried out a scoping review to provide an overview of the evidence base, as opposed to
narrowing down to aggregate sub-sets of evidence as in a systematic review [10,11]. In addition to
quantitative evaluations of interventions, we include qualitative studies describing the contexts of
interventions to enhance understanding of the drivers of prescribing and barriers to reducing prescribing.
We carried the review out in five stages: (1) identifying the research question; (2) identifying relevant
studies; (3) study selection; (4) charting the data; and (5) collating, summarising and reporting the
results [12].
2.1. Search Strategy
We conducted a systematic search guided by a combination of the PICO (Population, Intervention,
Comparison, and Outcome) and PICo (Population/Problem, Interest, Context) approach. Full
parameters are in Appendix A. PICO is usually used for quantitative reviews while PICo is used for
qualitative reviews. As we were interested in both human and animal antibiotic prescribing, we looked
for studies concerning people who supply antibiotics to sick people or animals, e.g., doctors and
other healthcare prescribers, drug sellers, informal doctors, pharmacists, community health workers,
veterinarians, farmers, and community animal health workers. We looked for any intervention aiming
to influence the prescribing or sale of antibiotics (formal and informal), e.g., communication and
education, stewardship programmes, treatment algorithms, delayed treatment, alternative treatments,
incentives, pricing, packaging, legislation, and peer or community oversight. Outcomes of interest were
measured improvement in antibiotic supply (e.g., reduction in unnecessary antibiotic prescriptions
and sales, health worker adherence to guidelines, etc.), as well as reported changes in knowledge
and attitudes around antibiotic prescribing, health outcomes (improved, unaffected, or adverse), and
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unintended consequences. Qualitative analysis of the contexts of interventions were also of interest,
e.g., implementation of a new policy and descriptions of attempts to influence prescribing.
To identify research in both the biological and social sciences, we searched MEDLINE, SCOPUS
and the Cochrane database of clinical trials. We also searched the 3ie database of impact evaluations and
the World Organisation for Animal Health (OIE) database. Search terms are included in Appendix B.
Table 1 contains the search results for each database searched. Time and resource constraints meant we
limited the date range to studies published during 2000–2017. A number of reviews already covered
publications before this cut off [4–6], and most studies were published post-2000, so we anticipated the
effect of the limitation to be minimal
Table 1. Search results.
Database Result
Scopus 20,083
Cochrane Central Register of Controlled Trials (CENTRAL) 3823
3ie Impact Evaluations 26
World Organisation for Animal Health (OIE) 0
Total 32,066
Total after duplicates removed 17,716
Total 2000–2017 15,142
2.2. Study Selection
Two research assistants reviewed the abstracts using the pre-defined inclusion and exclusion
criteria below. Borderline studies were discussed within the team. Table 2 shows the number of studies
included and excluded at each stage of the review process. From the initial figure of 15,142 search
results, the review includes 102 studies. Studies of interventions and intervention contexts were
separated out.
Inclusion criteria:
1. Reports on an intervention aiming to influence the prescribing and sale of antibiotics (formal and
informal), including the use of antibiotics to treat existing and suspected infections or to prevent
infection (e.g., antibiotic prophylaxis)
2. Any healthcare setting in a LMIC country
3. Outcomes:
• Externally measured change in antibiotic use/sale/prescribing
• Externally measured change in knowledge and attitudes around antibiotic use
• Self-reported change in antibiotic use/sale/prescribing
• Self-reported change in knowledge and attitudes around antibiotic use
• Observed change in the quality of antibiotics prescribed/sold
Or for “context studies”
• Studies that describe the contextual factors that influenced the effectiveness of interventions
Exclusion criteria:
- Studies of other ways of addressing antibiotic resistance, e.g., hygiene and infection and
prevention control such as vaccines, etc.
- Studies assessing adherence to antibiotics or medicine
- Studies of environmental transmission of antibiotics and antibiotic resistance
- Studies targeting other antimicrobials, and not targeting antibiotic use
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- Studies reporting on/intervening in patient demand for antibiotics and self-use
- Studies evaluating effectiveness of antibiotic treatment in clinical care, e.g., comparing
different treatments or ways of administering antibiotics, and reporting on clinical outcomes.
- For “context studies”, those studies that only described the context and not the
implementation or outcome of an intervention, e.g., a situation analysis
We carried out a detailed data extraction on the remaining 102 studies. For the 32 context studies, we
extracted qualitative data summarising their findings, and indicating the setting. For the 70 intervention
studies, we extracted descriptive information about the setting, intervention design and implementation,
study design, the author’s assessment of impact and our own.
Table 2. Selection process.
Stages
Abstract review 15,142
Excluded (did not meet inclusion criteria) 14,734
Included- 408
Full text review 408
Excluded—did not meet inclusion criteria on review 289
Duplicates (e.g., studies reporting same data) 4
Full text not available/not in English 13
Included—context studies 32
Included—intervention studies 70
Total—context and intervention 102
We looked at intervention effectiveness in more detail in a subset of studies (n = 41). Studies that
contained adequate information to assess effectiveness were included in this analysis. Two researchers
assessed studies for inclusion. Our assessment was based on the extent to which studies contained
complete information about the intervention and study design and thus whether necessary information
was available and how much confidence we had in their results (e.g., sample sizes, p-values, primary
outcomes, descriptions of the intervention, and identification of setting). Studies that comprehensively
discussed their methods and outcomes, and reported strategies to minimize estimation bias and
limitations were included. Studies were excluded if they were missing key study design or analysis
information such as the selection and measurement of outcomes, sample sizes, or p-values. Those
studies that interpreted results incorrectly or employed inconsistent methods for data collection
without justification or explanation were also excluded.
3. Results
We present summary statistics of the intervention studies included in the review. Table 3 shows
the number of studies included from each country. The largest number of studies are from China
(25 out of 70 studies), followed by India (6 studies). The high number of studies in China may be in
response to the major health reforms that took place there, e.g., in 2009, which saw the implementation
of Essential Medicine Lists, and, during 2011–2013, when there was a national campaign on improving
the use of antibacterial drugs. There are two cross-country studies—one in Brazil and Mexico, and the
other in Vietnam and Thailand. The rest of the studies were conducted in a single-country setting.
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Table 3. Country settings.
Country, by World Health Organisation Region
African region 15
Kenya 3
Mali 1
Malawi 1
Nigeria 3
South Africa 2
Sudan 2
Tanzania 3
Region of the Americas 5
Argentina 1
Brazil 2
Brazil and Mexico 1
French Guiana 1
European region 7
Republic of Srpska, Bosnia and Herzegovina 1
Serbia 2
Turkey 4
Eastern Mediterranean region 3
Pakistan 1
Iran 2
South-East Asian region 13
India 6
Indonesia 1
Nepal 3
Thailand 2
Thailand and Vietnam 1
Western Pacific Region 27
China 25
Vietnam 2
Total 70
3.1. Intervention Settings
We found no interventions addressing antibiotic prescribing in animal health. All intervention
studies were from human healthcare settings. The overwhelming majority of the reviewed studies
evaluated interventions at public prescribing facilities rather than private (see Figure 1). This trend is
particularly pronounced among studies conducted in primary care settings, where 15 out of 22 studies
examined the public sector. The exception was for pharmacies where seven out of nine studies were
conducted in the private sector. This is likely because pharmacies and drug shops are usually private
enterprises. In the hospital settings, 16 and 4 studies were conducted in public and private hospitals,
respectively, while in the remaining 16 it is unclear. This was due to the fact that studies mentioned
hospitals’ names but we were unable to judge whether the hospitals concerned are public or private
from available sources. Three other studies are not included in the figures: two were from mixed
public and private sector settings, and one was not clear.
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3.2. Types of Intervention
Table 4 presents the types of intervention conducted in different settings in a “gap map” format.
Interventions were classified into six broad categories: norms and standards, knowledge interventions,
decision support, supply chain, economic, and organisational/management systems. Blank cells
indicate that we found no evidence of an intervention being evaluated in that setting. The majority of
interventions have only been studied 1–3 times, and often in only one type of setting. The evidence
base is uneven, for example, there are 35 hospital-based studies and only nine in pharmacies. Only
educational interventions and the essential medicine policy have been evaluated in all settings.
Table 4 reveals a number of gaps in the evidence base though it should be noted that not all forms
of intervention are as relevant for each setting. “Audit/Feedback” and “Stewardship Programme” are
most often implemented in hospitals in comparison to other settings. This might reflect the ease of
monitoring and management in hospital settings, which are arguably more “closed”, as well as the
availability of expertise (e.g., infectious disease specialists) to perform key supportive roles. All five
studies conducted on essential medicines policy in primary care setting come from China where there
was major national policy reform. Although essential medicine policies are used widely, caution is
needed when considering the generalisability of those studies that report on a specific policy moment
and context.
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Table 4. Kinds of intervention, by setting.
Type of Intervention Hospital Primary Care Pharmacies Mixed Settings Total
Norms and standards (formal and informal)
Accreditation 1 1
Guidelines 3 3
Public reporting 4 4
Restrict over-the-counter sales 2 2
Prescription control 1 1
Knowledge
Audit/Feedback 8 2 10
Education 2 3 2 2 9
Education/Feedback 3 2 5
Education/Feedback/Regulation 2 2
Information 1 1
Decision support
Algorithms 1 2 3
Diagnostics 2 1 3
Supply chain
Decentralisation of Supply 1 1
Drug Delivery 1 1
Economic
Financial incentives 1 1
Pricing strategy 1 1
Health Insurance 2 1 3
Organisational/management systems
Essential Medicine Policy 2 5 1 8
Stewardship Programme 10 1 11
Total 36 22 9 3 70
Number of studies:
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3.3. Intervention Impact
We examined impact in a subset of 41 studies (out of 70), selected on the basis of their reporting
completeness. Studies were classifi as having positive, negative, mix d, or no effect, on the basis
of whether they reported improved or deteriorated prescribing rates, a combination, or no change,
respectively. Studies reporting decreases in antibiotic prescribing or increased adherence to appropriate
guidelines (e.g., choice of antibiotic, timing, dose, and duration of treatment) were classified as positive.
Studies reporting increased antibiotic prescribing rates or decreased adherence to guidelines (e.g.,
increased inappropriate antibiotic use, and use of restricted antibi tics) were classified as negative.
Table 5 shows the number of studies reporting each category of impact for each type of intervention.
Twenty-one studies show positive effects of the interventions, thirteen studies document mixed
effects, three studies show no effects and four studies indicate negative effects. Studies that had
mixed results were those that reported both positive and negative impacts on different prescribing
indicators and thus could not be categorised as wholly positive or negative. It should be noted that
sometimes this may reflect more complex analysis than the studies reporting positive (or negative)
results. The higher number of studies reporting positive or mixed results than negative or no results
may be indicative of publication bias. Table 5 includes all intervention types identified by the review
so there are some complete rows with no studies, e.g., supply chain interventions where the evidence
was found and included in Table 4, but excluded here because of reporting deficiencies.
Overall the evidence base is limited. Results are scattered and number of studies in each category
of result and intervention type is small; four being the maximum number of studies reporting positive
or mixed results for any intervention type. Out of the studies with positive results, the strongest
evidence is clustered around knowledge interventions, and there are four studies for audit/feedback
interventions and four for education/feedback interventions. Audit/feedback studies are those which
introduced primarily audit interventions (e.g., reviews of prescribing patterns according to guidelines)
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combined with feedback mechanisms (e.g., meetings and reports). Education/feedback studies are
those which introduced educational interventions (e.g., training sessions or courses and role play)
combined with feedback (e.g., meetings and group discussion). There are five positive evaluations of
stewardship interventions. Stewardship studies are those which combined policy review and change
(e.g., new targets, development of new guidelines, and incentives/disincentives), the creation of
antimicrobial/antibiotic resistance committees or working groups, education, audit and monitoring.
Out of studies reporting mixed results, four studies evaluated essential medicine policies as well as
public reporting (e.g., monitoring prescribing patterns and posting these publicly in/around health
settings). Studies documenting no or negative effects evaluated accreditation, diagnostics, essential
medicines policy, education, health insurance, and pricing intervention. More details of intervention
types are in Appendix C.
Table 5. Summary of intervention impacts.
Type of Intervention
Reported Impact
Total
Positive Mixed Negative No Effect
Norms and standards (formal and informal)
Accreditation 1 1
Guidelines 2 2
Public reporting 4 4
Restrict over-the-counter sales 2 2
Prescription control 0
Knowledge
Audit/Feedback 4 4
Education 2 1 4
Education/Feedback 4 1 4
Education/Feedback/Regulation 1 1
Information 0
Decision support
Algorithms 1 1 2
Diagnostics 1 1 2
Supply chain
Decentralisation of Supply 0
Drug Delivery 0
Economic
Financial incentives 1 1
Pricing strategy 1 1
Health Insurance 1 1
Organisational/management systems
Essential Medicine Policy 4 1 1 6
Stewardship Programme 5 1 6
Total 21 13 4 3 41
Number of studies:
Antibiotics 2018, 7, x FOR PEER REVIEW  7 of 26 
Decentralisation of 
Supply 
 1   1 
Drug Delivery 1    1 
Economic   
Financial incentives  1   1 
Pricing strategy    1   1 
Health Insurance 2 1   3 
Organisational/management systems  
Essential Medicine Policy 2 5 1  8 
Stewardship Programme 10  1  11 
TOTAL  36 22 9 3 70 
*Over the counter sales of antibiotics 184 
ber of studies 1–2 3–4 5–6 7–8 9–10 
Table 4 reveals a number of gaps in the evidence base though it should be noted that not all 185 
forms of intervention are as relevant for each setting. ‘Audit/Feedback’ and ‘Stewardship 186 
Programme’ are most often implemented in hospitals in comparison to other settings. This might 187 
reflect the ease of monitoring and management in hospital settings which are arguably more ‘closed’, 188 
as well as the availability of expertise (e.g. infectious disease specialists) to perform key supportive 189 
roles. All five studies conducted on essential medicines policy in primary care setting come from 190 
China where there was major national policy reform. Although essential medicine policies are used 191 
widely, caution is needed when considering the generalisability of these studies which report on a 192 
specific policy moment and context.  193 
3.3. Intervention impact 194 
We examined impact in a sub-set of 41 studies (out of 70), selected on the basis of their reporting 195 
completeness. Studies were classified as having positive, negative, mixed, or no effect, on the basis 196 
of whether they reported increases or decreases in prescribing rates, a combination, or no change. 197 
Table 5 shows the number of studies reporting each category of impact for each type of intervention.  198 
Table 5. Summary of intervention impacts 199 
Type of intervention Results  
Positive  Mixed Negative  No effect Total 
Norms and standards (formal and informal) 
Accreditation    1 1 
Guidelines 2    2 
Public reporting  4   4 
Restrict OTC*  2   2 
Prescription control     0 
Knowledge 
Audit/Feedback 4    4 
Education 2   1 4 
Education/Feedback 4 1   4 
Education/Feedback/ 
Regulation 
1    1 
.
Given that past reviews have found evidence suggesting that multifaceted interventions have
greater impact than single interventions, we checked if similar trends were observable in our studies.
We classified 21 studies a using multiple/mixed intervention strategies ( .g., education with feedback
or monitoring, or stewardship programmes which are multi-strategy) and 19 as using single change
pathways (e.g., one intervention modality, such as training). In one study, the approach was unclear.
This study was a survey of doctor’s prescribing practice which included questions on whether they had
received training on antibiotic use, however no details of the training were given. Table 6 shows that
although both single and multifaceted intervention produced positive and mixed results, the majority
of studies reporting mixed or positive results were multifaceted studies (positive and mixed combined
= 20 versus 13) and studies evaluating single pathway interventions reported no or negative effects
more frequently (negative and no effect combined = 1 versus 6). Indeed, none of the interventions
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classified as having mixed pathways reported negative results, and only one concluded there was no
effect (see Appendix C for more detail).
Table 6. Results, by intervention approach.
Reported Results
Intervention Pathway
Total
Single Mixed/Multifaceted
Positive 8 12 20
Mixed 5 8 13
Negative 4 0 4
No effect 2 1 3
Total 19 21 40
3.4. Prescribing and Intervention Contexts
The review identified 32 context studies, from 18 different countries. One study was multi-country [13]
while the rest described specific country contexts, which are listed in Appendix D. These studies described
the context of interventions aiming to address antibiotic supply in hospitals, primary care and pharmacy
settings, including public, private and informal providers. At least five studies looked specifically at
drug shops, community pharmacists and informal village doctors. Only one study describing use of
antibiotics in animal health was identified.
3.4.1. Knowledge of Antimicrobial Resistance and Appropriate Antibiotic Use
A number of studies identified limited knowledge of antimicrobial resistance (AMR) and of
appropriate drug use in a range of levels and sectors, for example surgeons in Jordon [14], tertiary and
primary care doctors in China [15], doctors in Laos [16], public and private doctors and pharmacists
in India [17] and drug sellers and pharmacists in Vietnam [18]. Bai et al. [15] found that, although
age and gender did not appear to be associated with knowledge scores in Chinese settings, it was
related to level of training, with more senior doctors performing well, and primary care doctors having
lower levels of knowledge than tertiary care doctors. In India, urban doctors seemed to have better
knowledge of AMR than rural ones [17]. Similarly, accreditation was not associated with improved
knowledge and prescribing among drug sellers and pharmacists in Vietnam; however, level of training
was, which in turn mapped onto urban–rural differences, with rural pharmacists being less qualified
than urban ones [18]. In contrast, Reynolds and Mckee’s [19] in depth study of knowledge and practice
among Chinese health workers found that awareness of resistance was high (although understanding
of mechanisms was limited), but despite this health workers still prescribed inappropriately due to
incentives listed in the next Section.
3.4.2. Practical Concerns and Diverse Influences on Antibiotic Prescribing
Research pointed to structural issues impeding healthcare workers’ ability to adhere to standards
and guidelines. For example, in Jordan, surgeons reported that appropriate drugs were absent [14], as
did pharmacists in India [20].
Beyond medicine availability, there appear to be myriad more subtle influencing factors. Studies of
doctors [17,19,20] identified the following factors as influencing prescribing: (i) inadequate diagnostic
facilities; (ii) lack of antibiotic guidelines; (iii) difficulty in observing patient progress (e.g., patients do
not return for test results and follow up, especially in poorer areas and in public clinics where they
cannot afford tests); (iv) poor intensive care facilities in rural areas; (v) patient demand for quick relief;
(vi) perceived patient expectation from past prescriptions; (vii) using up stock; and (viii) fear of losing
patients to competition (for private practices). Kotwani et al. [20] noted that doctors in the public sector
complained they did not have enough time during each consultation to cover patient history in depth
or to dissuade patients from wanting antibiotics.
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Pharmacists and drug sellers [17,20,21] had a similar list of influences: (i) patient demand; (ii) a
belief that cure is through antibiotics; (iii) competition from other pharmacy shops; (iv) antibiotic
sales promoting business; (v) the need to use up stock; and (vi) distance and costs of reaching care
facilities. Notably, public sector pharmacists in India reported overprescribing antibiotics to deal with
stock which was nearing its expiry date [20]. They did not return stock as it was a lengthy process
and more senior officials pressured them to use up stock. Drug shop owners in Tanzania attributed
their unnecessary sales of antibiotics to: customer demand, habit (“mazoea”), following inappropriate
health facility prescriptions, the need to make a profit (e.g., sell more expensive medicines), and also
the need to use up stock [22]. Significantly, for these private sector providers, they were disinclined to
refer patients to doctors, as it could result in their patients/customer base losing confidence in them;
thus, not selling drugs had short- and potentially long-term negative effects on profit.
An enlightening study from Vietnam [18] found that antibiotics were not the most profitable drug
for sellers, although it was the most commonly sold drug and the mark up did vary considerably;
antibiotics contributed 24% and 18% of total revenue in urban and rural pharmacies, respectively,
while herbal remedies contributed 24% and 27%.
3.4.3. Industry Influence
The influence of the pharmaceutical industry in providing information and incentives looms
large [17,23–25]. In Nigeria, both public and private hospitals’ doctors indicated that industry was
their primary source of information about drugs [23]. Indian doctors and pharmacists reported
coming under pressure and being offered incentives by pharmaceutical companies to use or sell drugs,
especially newer brands [17]. A study of doctors in Pakistan found that private sector doctors were
(reportedly) more susceptible to patient demand and to fear of losing patients to other providers than
their public sector counterparts, while public sector doctors were more likely to face problems with the
availability of drugs [26]. In Laos, doctors in provincial settings were more likely to receive information
from drug companies than doctors in district and central hospitals [16].
In their study of healthcare worker incentives in China, Reynolds and Mckee [19] found that some
doctors had arrangements with pharmaceutical companies to split the profits of extra sales. This was
in addition to the sanctioned cost recovery incentives (pre-2009 Chinese policy reforms).
3.4.4. Care and Responsibility
Studies identified additional cultures of care that influenced prescribing, suggesting the idea that
prescribers and sellers are primarily influenced by stock and profits may be an over simplification.
Indian pharmacists said the antibiotics they sold to poor patients was akin to social work [20]; and
Indian doctors said they prescribed antibiotics as prevention as their patients living with poor sanitation
and in unhygienic conditions were susceptible to infection [27]. There was also some reluctance for
pharmacists to challenge doctor’s authority by contesting prescriptions even if they knew they were
unnecessary [20].
3.4.5. Perceptions of Public Perception
Many of the studies include health worker’s perceptions of the public and their demands.
A common perception among doctors is that patients do not know about diseases and desire antibiotics
as a result [17]. In Nigeria [23], doctors say that when the public pay for health services, i.e., in private
hospitals, they expect medicines to be in their bills. Providers in both the public and private sector
stated that patient demand was a key factor in their prescribing [15,17,19,20,22,26–28]. However, it is
not clear what evidence these views are based on and whether they involve misperceptions on the
part of providers. In Sri Lanka, Tillekeratne et al. [28] found that although patients admitted expecting
drugs they were not specifically demanding antibiotics.
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3.4.6. Perspectives on Interventions
Some studies asked participants for suggestions of interventions to improve antibiotic use,
which included: creating public awareness, better healthcare provider communication, improved
diagnostic support, stricter implementation of guidelines, continuing education, and strengthening of
regulations [17]. There was an appetite for training [16,29]. For example, in Laos, a large majority of
doctors surveyed were in favour of educational programmes, whereas only 45% of doctors thought
guidelines were effective [16]; indeed, some doctors thought that guidelines were more of an obstacle
than a help (22%). South African medical students expressed a preference for e-learning platforms, but
significantly did not appreciate more interactive learning techniques such as “problem-based learning”
or “registrar interaction” (i.e., interaction with senior colleagues, in this case trainee specialists) [30].
This could reflect poor implementation of these learning modalities but it suggests that clarification is
needed of their role in education.
3.4.7. Policy Coordination
In Bangladesh, the progressive and once highly acclaimed National Drug Policy of 1982 has
not been maintained [31]; the regulatory institutions do not have power to curb prices or excess
use-generics less available, high mark up and sale of antibiotics for cough and fever. Bangladesh’s
experience serves as an important reminder, for example in relation to China’s apparently effective
essential drug reform, that there must be sustained investment into the comprehensive implementation
of policy especially those which address antibiotic use as part of other agenda’s such as universal health
coverage. A policy analysis in Namibia [32] highlighted inconsistency in national policy frameworks.
While treatment guidelines (e.g., HIV, malaria, tuberculosis, etc.) included recommendations about
antibiotics there was no overarching guideline for antibiotics; meanwhile, many of the antibiotics
included on the essential medicine list were not included in the treatment guidelines, and vice versa.
The study noted that lack of coordination between the committees developing these lists had led
to confusion with implications for clinical practice. Similarly, in China, doctors complained about
the number of new guidelines and no single authoritative source [19]. It is relevant that the only
international study, a survey of hospital-based stewardship initiatives [13], found that major barriers
included funding and human resources, suggesting sustainable implementation is a challenge.
3.4.8. Unintended Consequences
The management of fevers and common illnesses in outpatient settings is a significant problem.
A study examining the appropriateness of treatment in Papua New Guinea [33] found there was poor
compliance with the Integrated Management for Childhood Illness guidelines (ICMI) and that 40% of
children were not treated accurately: 29% received antibiotics when they should not have and 11% did
not receive antibiotics when they should have done. They observed that the prescription of antibiotics
was strongly influenced by the result of rapid diagnostic tests (RDTs) for malaria in feverish patients:
in children presenting with criteria for mild pneumonia (who should receive antibiotics), only 40%
were treated when the malaria RDT was positive, compared to 76% when the test was negative. This
suggests that health workers are primarily following RDT results and ignoring other clinical symptoms,
meaning the management of co-morbid bacterial and malarial infections are poorly managed. Several
studies point to the inadequacies of apparently simple methods (e.g., fever charts or RDTs) of managing
fevers and antibiotic use successfully at the community level [34,35]. Comprehensive follow up of
patients who may have co-morbid infections or who may have been misdiagnosed should be a priority.
3.4.9. Animal Health
Finally, only one context study covered use of antibiotics in agriculture. Aquaculture farmers
in Vietnam were asked about AMR [36]. Approximately half of farmers surveyed used antibiotics,
primarily as prophylaxis, which they bought directly from manufacturers not through veterinarians.
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Farmers were not aware of regulations about antibiotic use and their main sources of information
was from drug manufactures, including in seminars jointly arranged by the companies and
local government.
4. Discussion
The review confirms previous studies [4–6] that have found that multiplex interventions
combining different strategies to influence behaviour tend to have a higher success rate than
interventions based on single strategies. Another similarity to other reviews [4] is that many of
the interventions which worked well combined restrictive and enabling strategies, i.e., educational
techniques combined with forms of monitoring. To the best of the authors’ knowledge, this is the
largest review to document these patterns in LMIC countries.
The inclusion of evidence on prescribing contexts provides important additional insight. These
studies highlighted a web of interacting influences on prescriber behaviour that cannot be reduced
to simple motivations, such as profit. Instead, health system quality and availability, education,
perceptions of patient demand, bureaucratic processes, competition, and cultures of care all play a role.
Physician perceptions of patient demand [15,17,19,20,22,26–28] requires more attention as
observations do not always support this [28]. Indeed, elsewhere studies that have observed clinical
interactions have shown how doctors prescribe irrespective of patient demand [37] and that patient
satisfaction is not necessarily linked to whether a prescription was received [38], although these studies
are old. A more recent study from multiple European settings [39] found that, while patients frequently
hope for and expect antibiotics, it is less common for them to ask for them explicitly. Patients were
prescribed antibiotics considerably more often than they asked for them (54% compared to 10%,
respectively), and more than was clinically necessary. The same study found that, in general, patients
were satisfied with their consultations, whether prescribed antibiotics or not. Assessing the level
and influence of patient demand is difficult as research is often based on reported behaviour and
perceptions rather than observations.
It is striking the extent to which different providers blame others within the system: health
workers blame patients, pharmacists blame doctors and their incorrect prescriptions, and drug sellers
blame competitors saying patients will just “go somewhere else”. Such blame shifting highlights a
more general importance of interactions between people within the health system: pharmacists fear
challenging doctors’ prescriptions, drug sellers fear losing their customers, and many doctors and
pharmacists get a large proportion of their information about antibiotics from drug detailers who
also offer incentives. In discussions of interventions to address AMR, the temptation is to focus on
awareness raising and changing the behaviour of individuals, be they healthcare workers including
prescribers and pharmacists, or patients. However, the stewardship, supply and use of antibiotics in
human and animal healthcare is best viewed with a broad systemic lens [2,40]. This encompasses an
appreciation of how the behaviour of individuals is mediated by a range of structural and contextual
factors operating at different scales, which can affect individual agency and decision-making.
Scholars have advocated for a consideration of behavioural change interventions within the
context of everyday social practices [41]; for a whole system approach (at macro, meso and micro
levels) to analysing policy outcomes in the health sector [42]; for a consideration of formal and
informal health markets for drugs and services for both people and animals [7,43]; for an appreciation
of incentive structures in drug supply chains and the effects on over-the-counter drug retailers and
informal providers [44]; and for an approach to healthcare worker behavioural change interventions
that appreciates individual rationales as well as the contextual settings in which specific behaviours
are practiced [45]. The overall view is also one of decentred governance and regulation, which departs
significantly from traditional “command and control” models [46]. It is notable therefore that while a
majority of studies we identified in this review implemented multiplex interventions, most of these
took place within one health setting, e.g., a stewardship programme in a hospital. Very few studies
targeted different kinds of healthcare provider and different kinds of health settings. One exception
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was by Hoa et al [47] who attempted an educational programme for all providers in one district, public,
private, formal and informal and primary or secondary care. In this example, however, there was
a particularly high drop-out rate among informal providers illustrating the challenges of engaging
hard to reach groups in interventions. Moreover, important interactions between types of providers
are not being addressed and it is rare to find examples of whole system approaches which have been
recommended [2,40]. China provides one of the few examples of system-wide interventions at the
national and regional level. There is a need for coordinated action and research across multiple settings
and actors throughout and between the human and animal supply chain.
Significantly, our study was unable to identify a single study on interventions that addressed
prescribing behaviour for veterinary use of antibiotics, and only one context study on agricultural use.
Evidence is emerging that antibiotics critical for human health are being used in animal farming [48]
including colistin [49,50]. Research needs to address agricultural use of antibiotics and its overlap
with human health system in terms of the antibiotics used, healthcare personnel, and transmission
pathways of resistant pathogens. Measures to improve essential medicine use provides a precedent
for success [51]. The National Action Plan process provides an opportunity to facilitate this. In
particular, employing the “One Health” lens [52,53], taking the intersection among human, veterinary,
and environmental health into account, can help address the multi-sector nature of AMR and develop
systematic strategies to tackle this challenge.
In addition to the major lack of evidence documenting the effectiveness of interventions to improve
veterinary prescribing, this review has identified some gaps in the human evidence. Studies in hospitals
were most common, possibly as hospitals are more observable and controllable environments. The
overwhelming majority of studies evaluated interventions at public facilities. There was also a majority
of studies from urban areas, with less from rural areas, possibly because hospitals are over represented
in the data and tend to be in urban areas. Private providers, and in particular those in primary
care settings, is another gap. Informal private providers are especially underrepresented. Evidence
from LMICs suggests that rural and/or poor people extensively rely on healthcare services provided
by informal practitioners and suppliers of drugs [54,55]. Therefore, understanding the antibiotic
prescribing practices of the informal providers, and improving them, has important implications
for health of many marginalized people. There were no interventions in this review involving drug
retailers or the pharmaceutical companies despite their prominent role in the contextual studies.
Public understanding and demand is a critical piece of the puzzle and requires action but it
must be based on accurate understandings of lay knowledge and demand otherwise messaging and
educational interventions will fail. Research is needed into public views and their influence on demand
and prescriber behaviour. This should form part of a holistic view of supply and demand.
Our study has a number of limitations. While the literature search was extensive, it may not be
exhaustive and studies prior to 2000 were not included. The large number of heterogeneous studies
meant we were unable to assess quality of the evidence in detail and we did not compare or combine
the effects of selected studies. Further research is needed to assess the strength and magnitude of
effects for promising interventions. A majority of studies (n = 20) reported positive effects while
far fewer reported mixed, negative or no effects (n = 13, 4 and 3 respectively). This indicates that
publication bias may be an issue. Nevertheless, the review was able to identify trends and gaps in the
evidence base.
5. Conclusions
The evidence collected in this review comes from a range of health care settings, for example
hospitals, primary care, pharmacists or drug shops, and from interventions targeting different
types of health providers including doctors, nurses, and drug sellers. This review has identified
evidence on interventions to improve antibiotic use among providers in LMIC settings, which, in
the authors’ opinion, has not been well represented in previous reviews. The review found that
multiplex interventions that combine different strategies to influence behaviour tend to have a higher
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success rate than interventions based on single strategies. However, the evidence base is uneven
with hospital and urban contexts over-represented for interventions. There is much less evidence
on private providers, especially in primary care settings. Informal private providers who play a
major role in drug distribution in LMICs are especially underrepresented. Furthermore, there were no
interventions involving drug detailers or the pharmaceutical companies despite their prominent role
in the contextual studies. Strikingly, no study was identified that addressed veterinary prescribing
of antibiotics.
Evidence on prescribing contexts highlights a web of interacting influences on prescriber
behaviour including health system quality and availability, education, perceptions of patient demand,
bureaucratic processes, profit, competition, and cultures of care. These contextual studies underscore
the importance of interactions between different people within the health system. Although a majority
of studies implemented multiplex interventions, most of these took place within one health setting, e.g.,
a stewardship programme in a hospital. Very few studies targeted different kinds of health provider
and interactions across different kinds of health setting. There is an urgent need for coordinated
multi-actor studies including multiple settings, by taking a One Health approach, including agricultural
settings, and actors throughout the supply chain.
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Appendix A
Table A1. Search parameters.
Parameter Definition
Population
People who supply antibiotics to sick people or animals, e.g., doctors and other healthcare
prescribers, drug sellers, informal doctors, pharmacists, community health workers,
veterinarians, farmers, community animal health workers
Problem Unnecessary or inappropriate use of antibiotics
Intervention
Any intervention aiming to influence the prescribing or sale of antibiotics (formal and
informal), e.g., communication and education, stewardship programmes, treatment
algorithms, delayed treatment, alternative treatments, incentives, pricing, packaging,
legislation, peer or community oversight.
Comparison Not applicable. The review is not limited to controlled or comparative research designs.Studies which report on interventions with or without comparison groups are included
Context Hospital, outpatients, community, online, formal and informal systems in LMICs only.
Outcome
Primary: Measured improvement in antibiotic use (e.g., reduction in unnecessary antibiotic
prescribing, improved adherence to guidelines)
Other outcomes could include: Reported changes in knowledge and attitudes around
antibiotic use, e.g. health outcomes (improved, unaffected, or adverse), levels of antibiotic
resistance and unintended consequences
Appendix B
Search Terms
Bibliographic database searches combined the following sets of terms:
(1) Activity/Outcome of interest:
- antibiotic AND (prescribing OR sale OR prescribing OR prescription OR selling OR
availability OR consumption or dosage OR use)
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(2) Type of intervention:
- “Behaviour change”
- stewardship
- drug policy
- drug financing
- drug committee
- Marketing / social marketing
- Communication
- Outreach
- “community engagement”
- Evaluation
- Training
- Guideline$
- Algorithm
- curriculum
- “mass media”
- Information
- Television
- Radio
- Newspapers
- Booklets
- Pamphlet
- Posters
- Leaflets
- Advocacy
- Advice
- Fines
- Incentive$
- “financial incentive$”
- “financial intervention$”
- Fees
- formularies
- Tax
- Taxation
- Prohibit
- Prohibition
- Ban
- Regulation
- Legislation
- Reform
- Restrict
- Restriction
- Reminder$
- “Peer supervision”
- Subsidy
- Subsidi$ation
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- Peer support
- Reward$
- Targets$
- Feedback
- Planning
- Oversight
- “Goal setting”
- Audit$
- Monitoring
- Intervention OR Impact OR Pilot OR evaluation
Appendix C
Descriptions of interventions (n = 41) and factors associated with their effectiveness.
Norms and Standards
Guidelines were found to be effective in hospital settings, either when they were locally developed
or formed part of a comprehensive national reform programme. In the study by Zhang et al. [56], five
Chinese hospitals reduced their antibiotic consumption after the introduction of national guidelines.
However, very little information is provided about their implementation in hospitals and what
strategies may have supported it. Although the specificity of Chinese policy making contexts (e.g.,
a backdrop of major health and economic reforms, and a relatively strong government) must be
taken into account when considering generalisability, the study does provide observational evidence
(measured two years after their introduction) that guidelines can be part of effective response to the
overuse of antibiotics. Ristic et al. [57] recorded a positive effect of new guideline for prophylactic use
of antibiotics in Caesarean deliveries in a Serbian hospital. These guidelines were locally developed
and educational sessions accompanied their implementation suggesting a degree of ownership.
Public reporting interventions produced mixed results. Public opinion/expectations and peer
comparison appear to influence prescribing behaviours but in contrasting ways depending on the
disease, patient cohort and doctor’s ranking. Liu et al. [58], Tang et al. [59], Tang et al. [60], and
Yang et al. [61] reported effects of public reporting in primary care settings in China. Data on antibiotic
prescribing (percentage of prescriptions including antibiotics or injections, and cost) were collected and
individual doctors and facilities were compared and rankings were published publicly, e.g., on posters
outside facilities. The studies note differences in the effect of public reporting between diseases and
age groups according to public perception about appropriateness of prescribing for these categories
of illness or people. The intervention also influenced doctors differently according to their ranking,
and, in the study by Tang et al. [60], doctors categorised as “low prescribers” did not change their
habits, even though they could have reduced usage further. These findings indicate that social norms
around prescribing are interdependent and must be considered otherwise they can undermine even
apparently simple interventions.
Restricted over-the-counter sales: Santa-Ana-Tellez et al. [62] and Moura et al. [63] evaluated the
effect of controlling over-the-counter sales of antibiotics at pharmacies. National policies imposed
financial penalties and closure of businesses if antibiotics are prescribed without prescription. These
studies find mixed results but the implementation and reasons for the mixed results (e.g., reductions
in Mexico but not Brazil, or in urban or private settings rather than rural or public sector) are not
examined in detail.
Accreditation on its own is an insufficient motivator and regulator of antibiotic sales in private
sector drug shops. Minzi et al. [64] compared dispensing practices at certified drug sales outlets to
non-certified outlets. To gain accreditation, drug shops took part in a training to meet specified quality
criteria. After accreditation, the shop would then be allowed to sell a limited range of prescription-only
essential medicines and to receive additional support through regular supervision, refresher training,
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and commercial incentives such as training in business skills and access to microfinance. However,
adherence to prescribing guidelines was no better in accredited shops than non-accredited shops;
indeed, accredited shops were more likely to prescribe antibiotics without prescription and less likely
to refer patients appropriately. The authors noted that many of the staff who had received training and
gone through the accreditation process were no longer working in the shops, limiting the retention of
institutional knowledge from training interventions.
Knowledge Based Strategies
A number of interventions began with training sessions but supplemented them with
additional components.
Audit and feedback: Successful interventions involved repeated feedback combined with
supportive face-to-face educational strategies and monitoring, and similar approaches demonstrated
effectiveness in both hospitals and primary care settings. Awad et al. [65], Eltayeb et al. [66], Messina,
van den Bergh and Goff [67], and Shen et al. [68] evaluated the effects of auditing prescribing behaviour
and providing feedback in hospitals and primary care settings. Interventions spanned between six
months and one year. All interventions aimed at appropriate antibiotic prescribing and included
combinations of: audit and feedback, expert review, regular reporting to management/superiors,
reminders, recommendations and discussion of inappropriate prescribing, educational seminars and
face-to-face training sessions. Awad et al. [65] and Eltayeb et al. [66] tested different combinations of
intervention and found that audit and feedback alone was less effective than when combined with
other educational and monitoring components.
Education and feedback: To different degrees, Apisarnthanarak et al. [69], Bantar et al. [70],
Kafle et al. [71] and Opondo et al. [72] combined education, support and monitoring into multi-faceted
interventions. Components included: Theoretical and practical training sessions, tools (e.g., clinical
guidelines and job-aids), management processes (e.g., order/request forms), regular supervision from
senior colleagues, opportunities to discuss implementation of guidelines, facilitators/champions, and
face-to-face and peer-group discussion and feedback on performance. Three were hospital based and
one was in a primary care setting. These interventions had education at their core but combined
knowledge with restrictive and enabling approaches.
Education/feedback/regulation: Chuc et al. [73] took a regulatory focused approach to their
intervention in pharmacies in Vietnam, but combined it with education and peer-support mechanisms.
The intervention involved: visits from inspectors to assess compliance with prescription drug
regulation, educational sessions, and the identification of peer leaders to devise peer influence
strategies. As above, successful interventions combined restrictive and enabling approaches, and
importantly demonstrated effectiveness in private sector pharmacies. Notably, there was considerable
emphasis on formal regulatory institutions, including inspections, which would require adequate
resources to be effective over sustained periods of time.
Education: Training can be effective, but there is a gap between actual practice and reported
practice, with doctors underestimating or underreporting antibiotic prescribing. Two studies examined
straightforward training interventions. Shrestha et al. [74] evaluated a five-day training course on new
WHO lung health prescribing guidelines for primary care settings. Sun et al. [75] assessed knowledge,
attitude and practice of doctors in China. Doctors who had attended training reported that they
were less likely to prescribe antibiotics. However, a separate analysis of prescriptions revealed high
levels of antibiotic prescribing. Esmaily et al. [76] assessed a two-day training course for primary care
doctors on the principles of prescribing and found no improvement, although the intervention was
not extensive.
Decision Support
Algorithms: There is high quality evidence showing that algorithms can improve patient
management and reduce antibiotic prescribing in paper or electronic form. However, more specific
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diagnostic and case management approaches must be balanced with comprehensive follow up of patients,
otherwise cases could be missed. Shao et al. [77] evaluated a new algorithm to assist with the integrated
management of childhood illnesses. The quasi-experimental study documents a large and statistically
significant improvement in adherence to guidelines between the control (usual practice) and intervention
group. The study is conducted in primary care settings. Rambaud-Althaus et al. [78] evaluated the
effect of case management algorithms that assist with diagnosis and integrated management of
common illness among children in primary care settings. They compared a control group to two
different methods of algorithm support: paper-based and electronic (smart phone). While both paper
and smartphone-based algorithms are shown to decrease antibiotic use, they do so without being
able to identify which patients do need antibiotics and so compared to the control there were large
numbers of patients who needed antibiotics but who did not receive them. In effect, the control arm is
highly sensitive but not specific, whereas the intervention arms are more specific but less sensitive.
Patient follow up must be improved and is relevant to addressing resistance and tackling common
health problems.
Diagnostics: Misdiagnosis of bacterial diseases as flu, and misguided use of antibiotics for flu,
can be reduced using a rapid influenza test in outpatient settings. Bhavnani et al. [79] evaluated a
rapid diagnostic test for influenza in outpatients in rural Thailand and found that a negative influenza
result was associated with reduced antibiotic use. However, the scale of the reduction was modest,
suggesting that comprehensive reductions will require more than improved diagnostics.
Economic Strategies
Financial incentives: There is evidence that comprehensive changes to financial incentive structures
can have positive impacts and be achieved within public primary care settings. Yip et al. [80] evaluated
the effects of changing from a fee-for-service to a performance-based system in 28 primary care settings
in China. Operating within China’s public health insurance system, 30% of each facilities’ budget was
withheld, and they were subject to a performance review. Based on the results of the review, the
money that had been withheld was shared among the top performing facilities. The study documents
decreased antibiotic use, mostly due to reduced injectable antibiotics. Centralised management was
important to the effectiveness of financial incentives in this case.
Organisational/Management Strategies
Stewardship programme: Comprehensive stewardship campaigns using multiple approaches
resulted in substantial reductions in antibiotic use and sales in both hospitals and pharmacies.
Kallel et al. [81], Ma et al. [82], Ozkurt et al. [83], and Zhang et al. [84] evaluated effects of stewardship
programme at secondary or tertiary hospitals while Markovic´-Pekovic´ et al. [85] studied effects
at pharmacies. The interventions involved: The formation of expert interdisciplinary groups to
provide oversight and guidance, knowledge dissemination, clinical training, academic engagement
(e.g., participation in conferences and seminars), monitoring, feedback, data management and verification,
the development of new guidelines and targets and financial penalties. In the study by Ma et al. [82],
doctors not meeting the new standards had their salary deducted, and, in the study by Markovic´-Pekovic´
et al. [85], pharmacists were fined for selling antibiotics over the counter. This latter study with
pharmacists also includes public awareness campaigns and policy coordination, as part of a larger
national stewardship effort. However, the authors also found that pharmacists gave less oral or written
advice alongside antibiotic sales, which they suggested could indicate an attempt to obscure banned
practices. Increased restriction on sales could prompt sellers to sell drugs in more underhanded
or unsafe ways. Magedanz et al. [86] addressed a stewardship programme and in particular an
audit-and-feedback component focusing on restricting certain classes of antibiotic. This resulted in
uneven patterns of use, with success is reducing use of some antibiotics seemingly driving increased
use of others. While restricting classes of antibiotics can be effective especially in the short term, it
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may drive increased use for other drugs which may not be sustainable over the longer term when
reductions in usage across the board are required.
Essential medicine policies had mixed effects and highlight the need to integrate action on antibiotic
use with other health system initiatives. Ding et al. [87] and Wei et al. [88] addressed the effects of China’s
essential medicines policy on levels of antibiotic use in hospitals while Song et al. [89] and Yao et al. [90]
studied its effects in primary care settings. Essential medicine policies are multifaceted involving:
establishing a list of essential drugs, supply chain measures and price control. Results were mixed
across regions, urban–rural settings and different facilities, depending on implementation. Use of some
antibiotics increased or decreased depending on their inclusion on the lists, as did cost of treatment.
Some interventions coincided with other initiatives (e.g., hospital-level stewardship programme)
which made it hard to separate effects, including from wider health system reform (e.g., “no mark-up”
policy) and delivery (e.g., health insurance programmes) and could be responsible for changes in
use. Yang et al. [91] evaluated China’s national essential medicine policy and found that, although
availability and cost of essential drugs increased, there was no reduction in the number of antibiotics
prescribed. This is likely due to the fact that the policy focuses on extending access to quality and
reasonably priced drugs and not explicitly on prudent use of drugs (see below). Essential medicine
lists provide a policy framework for implementing change at scale but prudent use of antibiotics needs
to be considered in their design, otherwise they will not lead to significant reductions in use.
Studies with Negative Results
Four studies documented increased rates of antibiotic prescribing or increased levels of
inappropriate antibiotic use. The interventions associated with these negative findings were Nigeria’s
essential drug policy [92], China’s national health insurance policy [93], changes in fee structure in
Nepal [94] and rapid malaria diagnostics [95]. All interventions were conducted at the national level
and, with the exception of the malaria RDT, their focus was on improving access to medicines rather
than aiming to reduce antibiotic use or to improve antibiotic prescribing practices (hence their authors
would not view them as unsuccessful or as having “negative” results). We have described these
separately to emphasise the need to align policies and consider unintended consequences. In the case
of the Malaria RDTs [95], improvements in diagnosing malaria were not matched by improvements in
the diagnosis of bacterial disease. An unintended consequence of malaria RDTs is that the reductions
in unnecessary use of antimalarial drugs have been offset by increases in antibiotics prescription in
cases where the RDT is negative for malaria. Unless action on extending access is coordinated with
action to improve use there is potential for interventions to be in conflict.
Appendix D
List of context studies and countries
- Bangladesh [31]
- China [15,19,29]
- India [17,20,27,34,96,97]
- Jordan [14]
- Laos [16]
- Mexico [98]
- Namibia [32]
- Nepal [24]
- Nigeria [23]
- Pakistan [25,26]
- Papua New Guinea [33]
- South Africa [30]
- Sri Lanka [28]
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- Sudan [21]
- Tanzania [22,35,99,100]
- Thailand [101]
- Turkey [102,103]
- Vietnam [18,36]
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